Real-world efficacy of second-line therapies for Helicobacter pylori : a population-based study
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Chuan-Guo Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing Friendsh…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Drug Therapy, Combination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Friendship Hospital Seed Plan.
Abstract (Originalsprache)
Background
With the increasing prevalence of antibiotic resistance, real-world data on the optimal empirical second-line therapy for Helicobacter pylori are still limited.
Objectives
To evaluate the real-world efficacy of various second-line therapies for H. pylori. Patients and methods This was a retrospective population-based cohort study of all H. pylori-infected patients who had received the second-line treatment after the failure of primary clarithromycin triple therapy in Hong Kong between 2003 and 2018. The retreatment success rates of different second-line therapies were evaluated.
Results
A total of 7591 patients who received second-line treatment were included. Notably, the most commonly prescribed regimen was still clarithromycin triple therapy, but the frequency of use had decreased from 59.5% in 2003–06 to 28.7% in 2015–18. Concomitant non-bismuth quadruple therapy had emerged as the commonest regimen (from 3.3% to 43.9%). In a validation analysis, the sensitivity and specificity of retreatment-inferred second-line treatment failure were 88.3% and 97.1%, respectively. The overall success rate of second-line therapies was 73.6%. Bismuth quadruple therapy had the highest success rate of 85.6%, while clarithromycin triple therapy had the lowest success rate of 63.5%. Specifically, bismuth/metronidazole/tetracycline quadruple, metronidazole/tetracycline triple, levofloxacin/metronidazole/tetracycline quadruple, rifabutin/amoxicillin triple and amoxicillin/levofloxacin triple therapies had relatively higher success rates over 80%. Age, treatment duration, baseline conditions and first-line treatment used were associated with success rate.
Conclusions
Bismuth quadruple therapy was the most effective second-line regimen for H. pylori in this real-world study. Despite a very low success rate, clarithromycin-containing triple therapies were still commonly used as second-line regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China.
ORCID-Profile: Chuan-Guo Guo
Förderung
- National Natural Science Foundation of China
- Beijing Friendship Hospital Seed Plan
Zitieren
APA
Guo, C. G., Jiang, F., Li, Y., Chen, Y., Wu, J., Zhang, S., & Leung, W. K. (2024). Real-world efficacy of second-line therapies for Helicobacter pylori : a population-based study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae224
Vancouver
Guo CG, Jiang F, Li Y, Chen Y, Wu J, Zhang S, et al. Real-world efficacy of second-line therapies for Helicobacter pylori : a population-based study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae224
BibTeX
@article{Guo2024,
author = {Guo, Chuan-Guo and Jiang, Fang and Li, Yueyue and Chen, Yijun and Wu, Jialin and Zhang, Shutian and Leung, Wai K},
title = {Real-world efficacy of second-line therapies for Helicobacter pylori : a population-based study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae224}
}
EUVIMED